目的: 对我国医保药品准入谈判中量价互换的运行逻辑和实现条件进行分析和阐述。方法: 基于管理学、经济学等相关学科理论,探讨市场运行中数量和价格的互动关系,结合医保药品准入谈判中量价关系的特点,阐述该项工作中量价互换政策意图的实现条件和机制,并对各种障碍因素的测量方法进行探讨。结论: 医保准入谈判中的量价关系非常复杂,医保和厂商双方对后续运行的障碍要有清晰的认知,才能合理决策,推进该项工作顺利开展并惠及广大民众。
Abstract
Objective: The paper analyzed the operational logic and conditions for the quantity-price tradeoff in the negotiation of medical insurance drug access in China. Methods: Based on theories from management, economics, and related disciplines, this study explored the interactive relationship between quantity and price in market operations. It combined the characteristics of quantity-price relationships in the negotiation of medical insurance drug access to expound on the conditions and mechanisms for the realization of policy intentions in this work. It also discussed the measurement of various obstacles. Conclusions: The quantity-price relationship in the negotiation of medical insurance drug access is highly complex. Both the healthcare security departments and manufacturers need to have a clear understanding of the obstacles to subsequent operations, in order to make reasonable decisions, promote the smooth implementation of this work, and benefit the general public.
关键词
医保谈判 /
目录管理 /
量价互换
Key words
medical insurance negotiation /
catalogue management /
quantity-price tradeoff
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 顾彦.药价谈判“以量换价”对接医保实现“三赢”[J].中国战略新兴产业,2016(13):88-90.
[2] 陶立波.医药带量集采“以量换价”的经济学解析[J].卫生软科学,2020,34(05):3-5.
[3] 黎东生,白雪珊.带量采购降低药品价格的一般机理及“4+7招采模式”分析[J].卫生经济研究,2019,36(8):10-12.
[4] 陈江飞,葛惠雄,苗彩云.国谈药政策落地难的解法[J].中国医院院长,2024,20(04):80-83.
[5] 岳东洋,吴明.国家医保准入谈判对创新药使用量和销售金额的影响研究[J].卫生软科学,2023,37(10):17-22.
[6] 刘晓婕,蒋虹丽,陈文.国家医保谈判对公立医院抗肿瘤药物采购费用、数量及结构的影响:以EGFR-TKI靶向药物为例[J].中国卫生资源,2023,26(04):370-376.
[7] AFRIAT S N.The market: equilibrium, stability, mythology[M].London: Taylor and Francis, 2006.
[8] 阿弗里德·马歇尔.经济学原理[M].北京:华夏出版社,2013.
[9] 陶立波,王芳旭.医改政策中量价挂钩、以量换价问题的思辨[J].中国卫生经济,2023,42(12):13-15.
[10] 陶立波,吴瑶.医保国谈药落地问题的交易成本视角分析[J].卫生软科学,2022,36(11):67-70.
[11] 廖化.国家谈判药品落地的陕西实践[J].中国医疗保险,2020(09):44-46.
[12] 丁锦希,李轶,韩晓睿,等.国家医保目录动态调整机制的改革成效与发展思路[J].中国医疗保险,2021(05):40-46.
[13] 刘心怡,张璐莹,陈文.国家谈判药品的医保管理实践案例研究[J].中国医疗保险,2021(03):34-37.
[14] 谢金平,邵蓉.国家医保谈判药品省级落地管理典型模式研究[J].中国卫生经济,2020,39(06):42-46.
[15] 黄德斌.突破药品“进院难”[J].中国社会保障,2021(09):31.
[16] 赵志刚,董占军,刘建平.中国医疗机构药品评价与遴选快速指南[J].医药导报,2020,39(11):1457-1465.
[17] 张方,张大为,孟丽华,等.药品临床价值评估指标体系的构建研究[J].中国药学杂志,2017,52(08):706-710.
[18] 李欣雨,徐娟.我国医保谈判药品“双通道”管理政策执行困境及推进策略[J].中国药房,2024,35(08):906-911.
